Development of novel cell and gene therapies

细胞工程中心(CCE)正致力于开发和改进癌症细胞疗法，包括树突状细胞(DC)疗法、嵌合抗原受体(CAR)T细胞疗法和表达肿瘤抗原特异性T细胞受体(TCR)的T细胞。该实验室还在努力改进用于生产CAR T细胞和诱导多能干细胞(IPS)的方法，用于再生医学应用。 CCE新生产管理(NPM)实验室已经开发并正在制造几种汽车T细胞疗法。CD22-CAR T细胞、CD19/CD22双特异性T细胞和CD19/CD22双顺反子T细胞正在研制中，用于治疗儿童B细胞急性淋巴细胞白血病。该实验室还开发了CD19/CD20双特异性CAR T细胞，不久将用于治疗淋巴瘤患者。该实验室已经开发出使用全自动仪器制造CD19/CD22-CAR T细胞的程序。这一自动化仪器已被用于开发抗Glypcan-3CAR T细胞，用于治疗肝细胞癌患者。该实验室还比较了用不同方法制造的同一辆车T细胞的特性，发现了一些重要的差异。 人乳头瘤病毒(HPV)感染与许多癌症有关。NPM实验室已经开发出一种方法来生产T细胞，这种T细胞表达针对HPV-16癌蛋白E7的T细胞受体(TCR)。这些细胞正被用于治疗HPV相关的宫颈癌和口咽癌患者。该实验室最近还完成了KK-LC-1特异性TCR工程T细胞的开发。这些细胞还将用于治疗HPV相关癌症患者。 细胞处理实验室正在与国家眼科研究所的研究人员合作，开发从血液中分离的CD34+细胞制造iPS细胞的方法，并在视网膜色素上皮(RPE)细胞中分化iPS细胞。RPE细胞将用于治疗老年性黄斑变性患者。

The Center for Cellular Engineering (CCE) is working to develop and improve cancer cellular therapies including Dendritic Cell (DC) therapies, Chimeric Antigen Receptor (CAR) T cell therapies and T cells engineered to express T cell receptors (TCRs) specific to tumor antigens. The laboratory is also working to improve the methods used to produce CAR T cells and induced pluripotent stem (iPS) cells for regenerative medicine applications. The CCE New Production Management (NPM) laboratory has developed and is manufacturing several CAR T cell therapies. CD22-CAR T cells, CD19/CD22-bispecific T cells and CD19/CD22-bicistronic CAR T cells are being manufactured in order to treat pediatric patients with B cell acute lymphoblastic leukemia. The laboratory has also developed CD19/CD20-bispecific CAR T cells which will soon be used to treat patients with lymphoma. The laboratory has developed procedures to manufacture CD19/CD22-CAR T cells using a completely automated instrument. This automated instrument has been used to develop anti-Glypican-3 CAR T cells which are being used to treat patients with hepatocellular carcinoma. The laboratory has also compared the characteristics of the same CAR T cells manufactured using different methods and found some important differences. Human Papillomavirus (HPV) infection is associated with a number of cancers. The NPM laboratory has developed a method to produce T cells that express a T cell receptor (TCR) that is specific for the HPV-16 oncoprotein E7. These cells are being used to treat patients with HPV-associated cervical and oropharyngeal cancers. The laboratory has also recently completed the development of KK-LC-1 specific TCR engineered T-cells. These cells will also be used to treat patients with HPV-associated cancers. The Cell Processing Laboratory is collaborating with investigators in the National Eye Institute to develop methods to manufacture iPS cells from CD34+ cells isolated from the blood and to differentiate the iPS cells in retinal pigment epithelial (RPE) cells. The RPE cells will be used to treat patients with age related macular degeneration.